Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.9807
-0.0183 (-1.83%)
Aug 14, 2025, 11:07 AM - Market open
Coherus Oncology Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Coherus Oncology stock ranges from a low of $1.05 to a high of $7.00. The average analyst price target of $4.68 forecasts a 377.21% increase in the stock price over the next year.
Price Target: $4.68 (+377.21%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 29, 2025.
Analyst Ratings
The average analyst rating for Coherus Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +613.78% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | +7.07% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +613.78% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +613.78% | Jan 23, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +511.81% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
44.75M
from 266.96M
Decreased by -83.24%
Revenue Next Year
108.57M
from 44.75M
Increased by 142.61%
EPS This Year
-1.16
from 0.25
EPS Next Year
-0.73
from -1.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.2M | 196.0M | 185.6M | ||
| Avg | 44.8M | 108.6M | 135.8M | ||
| Low | 20.6M | 60.8M | 88.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -79.7% | 338.1% | 71.0% | ||
| Avg | -83.2% | 142.6% | 25.1% | ||
| Low | -92.3% | 35.8% | -18.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.01 | -0.27 | -0.47 | ||
| Avg | -1.16 | -0.73 | -0.63 | ||
| Low | -1.21 | -1.13 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.